Last updated: February 27, 2026
What is the drug associated with NDC 46122-0577?
NDC 46122-0577 refers to Cenegermin-bkbj (Oxervate), a topical ophthalmic solution indicated for the treatment of neurotrophic keratitis (NK) in adults. It is marketed by Dompé. The drug was approved by the FDA in August 2018.
Current Market Status
Cenegermin entered a niche segment targeting a rare eye disorder. The orphan drug designation implies limited but significant market potential driven by the unmet medical need.
Market size estimation
The global prevalence of neurotrophic keratitis is approximately 5-10 cases per 100,000 individuals, according to the American Academy of Ophthalmology[1]. The total addressable patient population in the U.S. is estimated at:
| Population Segment |
Approximate Number (U.S.) |
| Adults with NK |
16,500 - 33,000 |
Based on this, the treated population is small but involves high-cost, specialized therapy.
Competitive landscape
- Existing therapies: Concomitant treatments include supportive measures, artificial tears, and surgical interventions. No approved pharmacological advanced treatments prior to Cenegermin.
- Potential competitors: Developments in regenerative medicine, including nerve growth factor analogs, are ongoing, but none have reached commercialization.
Market penetration factors
- Regulatory exclusivity: 7-year market exclusivity in the U.S. (since 2018).
- Physician adoption: Limited due to the rare diagnosis and high cost.
- Supply chain constraints: Initial manufacturing constraints slowed uptake post-launch.
Pricing and Revenue Projections
Current pricing
- Approved label price (ASP) in the U.S.: approximately $2,500 - $3,000 per vial (each vial contains 0.2 mL, applied as one drop twice daily for 8 weeks).
Cost considerations
- Typical treatment course involves 8 weekly injections, equating to roughly 16 vials.
- Total treatment cost: approximately $40,000 - $48,000 per patient.
Revenue forecast (next 5 years)
| Year |
Estimated U.S. Patients Treated |
Revenue (USD millions) |
| 2023 |
500 |
20–24 |
| 2024 |
1,000 |
40–48 |
| 2025 |
1,500 |
60–72 |
| 2026 |
2,000 |
80–96 |
| 2027 |
2,500 |
100–120 |
Assumptions: A gradual adoption rate as physicians become familiar with the drug and treatment guidelines and as insurance coverage expands.
Sensitivity factors
- Increased awareness via clinical guidelines could double or triple patient numbers.
- Price adjustments may be limited by payer negotiations due to the high therapy cost.
- Off-label use or expanded indications could expand market size.
Regulatory and Policy Impact
- Orphan drug status grants 7-year exclusivity, postponing biosimilar entry.
- Reimbursement is facilitated through Medicare and private insurers but remains subject to prior authorization.
- Any policy changes favoring orphan drugs or value-based pricing could impact revenue and price.
Conclusion
While NDC 46122-0577 (Cenegermin) targets a rare condition, market potential is constrained by the small population size but allows for high per-patient revenue. Projected annual U.S. sales may reach over $100 million by 2027, assuming steady adoption and favorable coverage. Price points are likely to remain stable unless significant policy shifts occur.
Key Takeaways
- Cenegermin treats a rare neurotrophic keratitis; large market size is limited but high-cost.
- U.S. treatment costs hover around $40,000 per course.
- Revenue projections show growth, reaching approximately $100 million by 2027.
- Market penetration depends on physician familiarity, insurance coverage, and supply chain stability.
- Regulatory exclusivity and limited competition support sustained pricing.
FAQs
-
What is the main indication for NDC 46122-0577?
Treatment of neurotrophic keratitis in adults.
-
How is the drug administered?
As an ocular solution, two drops twice daily for about 8 weeks.
-
What are the primary market challenges?
Small patient population, high treatment costs, and limited awareness among clinicians.
-
Could biosimilars impact pricing in the future?
Yes, after patent and exclusivity periods, biosimilars could enter the market, potentially reducing prices.
-
Are there regulatory risks affecting market projections?
Limited, given the orphan drug status, but policy shifts or new approvals for alternative therapies could alter dynamics.
References
[1] American Academy of Ophthalmology. (2020). Neurotrophic keratitis: Epidemiology and clinical features. AO Journals.
[2] FDA. (2018). Oxervate approval letter. U.S. Food and Drug Administration.
[3] IQVIA. (2022). U.S. ophthalmology market data. IQVIA.
[4] Dompé. (2023). Oxervate prescribing information.
